Overview

A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

Status:
Completed
Trial end date:
2020-03-11
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
Phase:
Phase 2
Details
Lead Sponsor:
Ironwood Pharmaceuticals, Inc.
Collaborator:
Allergan Sales, LLC